Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

126 results about "ANXIETY COMPLEX" patented technology

Certain vitamins such as B-complex are stimulatory and will cause anxiety and even panic attacks in some people. Minerals such as copper, manganese and others are also stimulatory. Certain herbs such as ginseng and eluthero are also somewhat stimulatory and can cause anxiety.

Method of treating depression, mood disorders and anxiety disorders using neuromodulation

The present invention involves a method and a system for using electrical stimulation and / or chemical stimulation to treat an affective disorder, such as depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and / or catheter that is in communication with a predetermined site which is coupled to a signal generator and / or infusion pump that release either an electrical signal and / or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and / or anxiety.
Owner:ADVANCED NEUROMODULATION SYST INC

Method of treating mood disorders and/or anxiety disorders by brain stimulation

ActiveUS20060064138A1Alleviation and modulation of moodAlleviation and modulation of and anxiety disorderElectrotherapyDiagnostic recording/measuringElectrical stimulationsInfusion pump
The present invention involves a method and a system for using electrical stimulation and / or chemical stimulation to treat depression. More particularly, the method comprises surgically implanting an electrical stimulation lead and / or catheter that is in communication with a predetermined site which is coupled to a signal generator and / or infusion pump that release either an electrical signal and / or a pharmaceutical resulting in stimulation of the predetermined site thereby treating the mood and / or anxiety disorder.
Owner:ADVANCED NEUROMODULATION SYST INC

Methods of treating anxiety disorders

Disclosed are methods of treating an anxiety disorder, e.g., obsessive compulsive disorder, in an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to restore normal monoaminergic tone within the synapse.
Owner:OREXIGEN THERAPEUTICS INC

mGluR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
Owner:SCHERING CORP

Treatment of anxiety with eszopiclone

InactiveUS20080175903A1Improved liabilityImprove securityBiocideNervous disorderANXIETY COMPLEXAnxiety
The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a subsedative dosage of zopiclone particularly eszopiclone.
Owner:SEPACOR INC

mGluR1 Antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
Owner:SCHERING CORP

Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

This invention is directed to indolone derivatives which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.
Owner:H LUNDBECK AS

Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof

The present invention relates to pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of depression and / or anxiety.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Scopolamine for the treatment of depression and anxiety

ActiveUS20060270698A1Reduce depressionQuickly and efficiently treating unipolar and bipolar depressionBiocidePowder deliveryANXIETY COMPLEXActive agent
Provided herein are methods and compositions for the treatment of depression and anxiety. The compositions comprise scopolamine, or an analog thereof, and can optionally include one or more psychoactive agents. Further provided is an inhaler comprising scopolamine, or an analog thereof, in a pharmaceutically acceptable carrier.
Owner:UNITED STATES OF AMERICA

Slow release medicinal composition for treating anxiety and its preparing method

The present invention provides a kind of slow released medicinal composition for treating anxiety, and features that the slow released medicinal composition is slow released medicinal preparation with tadosporin citrate in effective quantity as the active component and pharmaceutically acceptable supplementary material. By means of the action of the slow releasing material, tadosporin citrate is released slowly to generate slow and smooth blood medicine level without peak valley phenomenon and with raised patient compliance. The present invention has reduced medicine taking times and convenient taking.
Owner:SICHUAN CREDIT PHARMA

Oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis

The invention relates to an oral traditional Chinese medicine preparation for treating melancholia and anxiety neurosis, which is prepared by adopting the following raw materials of traditional Chinese medicines in parts by weight: 15+ / -3 of roasted astragalus root, 10+ / -2 of American ginseng, 10+ / -2 of white atractylodes rhizome, 10+ / -2 of tall gastrodia tuber, 10+ / -2 of medlar, 10+ / -2 of prepared rehmannia root, 10+ / -2 of white peony root, 10+ / -2 of radix salviae miltiorrhizae, 10+ / -2 of angelica, 10+ / -2 of rhizoma ligustici wallichii, 10+ / -2 of herba epimedii, 15+ / -3 of spine date seed, 10+ / -2 of tuckahoe, 10+ / -2 of rhizoma anemarrhenae, 10+ / -2 of rhizoma cyperi, 10+ / -2 of radix bupleuri, 10+ / -2 of TurmericRoot-tuber and 6+ / -1.2 of roasted licorice. The observation of clinical curative effect proves that the total effective rate of the invention for treating the anxiety neurosis is 92.2%; the total effective rate of the invention for treating the melancholia is 91.0%. The curative effect of the oral traditional Chinese medicine preparation is similar to the curative effect of the western medicines of buspirone for treating the anxiety neurosis and fluoxetine for treating the melancholia. Moreover, the traditional Chinese medicine preparation has no obvious toxic or side effect and can be taken for a long time. The preparation has small dose, easy release of the effective components of the medicine, quick absorption, full exertion of the medicine effect, convenient carrying and easy taking and is beneficial to large-scale production.
Owner:HOSPITAL NO 3 CPLA

Method of treating an anxiety disorder

Anxiety disorders, such as panic disorder, agoraphobia, obsessive-compulsive disorder, social phobia, post-traumatic stress disorder, generalized anxiety disorder, specific phobia, or the like, are treated by administering an effective amount of at least one adenosine A2A receptor antagonist to a patient in need thereof, optionally in combination with an anxiolytic(s) other than the adenosine A2A receptor antagonist.
Owner:KYOWA HAKKO KIRIN CO LTD

Devices and methods for treatment of anxiety and related disorders via delivery of mechanical stimulation to nerve, mechanoreceptor, and cell targets

Presented herein are systems, methods, and devices that provide for stimulation of nerves and / or targets such as mechanoreceptors, tissue regions, mechanoresponsive proteins, and vascular targets through generation and delivery of mechanical vibrational waves. In certain embodiments, the approaches described herein utilize a stimulation device (e.g., a wearable device) for generation and delivery of the mechanical vibrational waves. As described herein, the delivered vibrational waves can be tailored based on particular targets (e.g., nerves, mechanoreceptors, vascular targets, tissue regions) to stimulate and / or to elicited particular desired responses in a subject. As described herein, in certain embodiments, the delivery of mechanical stimulation to a subject provides for treatment of anxiety.
Owner:APEX NEURO HLDG INC

Fused tricyclic mGluR1 antagonists as therapeutic agents

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
Owner:SCHERING CORP

Application of P2X2 receptor agonist or opening agent in preparation of anti-depression or anti-anxiety drugs

The invention discloses an application of a P2X2 receptor agonist or a P2X2 receptor opening agent in preparation of anti-depression or anti-anxiety drugs. According to the present invention, experiment research results confirm that: the P2X2 receptor agonist or the P2X2 receptor opening agent has an anti-depression and / or anti-anxiety effect, such that the P2X2 receptor agonist or the P2X2 receptor opening agent can be used for preparing anti-depression or anti-anxiety drugs, and can be adopted to screen prevention and treatment target points of anti-depression and / or anti-anxiety drugs and screen early stage pre-warning and clinical diagnostic reagents of depression and / or anxiety so as to provide broad application prospects.
Owner:誉神(广州)医学科技有限公司

3-imino-2-indolones for the treatment of depression and/or anxiety

This invention is directed to indolone derivatives which are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and / or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and / or anxiety. This invention also provides a method of treating depression and / or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.
Owner:H LUNDBECK AS

Partial mGluR5 antagonists for treatment of anxiety and CNS disorders

Provided is a method of treating conditions and disorders for which full mGluR5 antagonists are potentially effective, such as, e.g., anxiety, epilepsy, schizophrenia and other psychotic disorders, Parkinson's disease, addictive disorders, and the like in a subject in need of such treatment, comprising administration to such subject of a therapeutically effective amount of a partial, non-competitive mGluR5 antagonist compound of the invention. Specific examples of partial MgluR5 antagonists provided include those compounds having the formula: wherein: Z is, independently N or —CH—, provided that one, and only one Z is N; R is halogen (e.g., Br, F and the like), alkyl (e.g., methyl), alkenyl (e.g., CH═CH2, aryl (e.g., phenyl), heterocyclic (e.g., thiophenyl).
Owner:VANDERBILT UNIV

Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety

The present invention relates to cis-derivatives of formula wherein R1, R2, and R3 are as defined herein and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors). By virtue of their efficacy as SERT inhibitors, the compounds of the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and / or in the treatment of anxiety.
Owner:F HOFFMANN LA ROCHE & CO AG

4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders

Compounds of general formula I R<1 >is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, and pyridine N-oxide; R<2 >is independently selected from ethyl and isopropyl; R<3 >is independently selected from hydrogen and fluoro; R<4 >is independently selected from -OH, -NH2 and -NHSO2R<5>; and R<5 >is independently selected from hydrogen, -CF3 and C1-C6 alkyl, or salts thereof or separate enantiomers and salts thereof; where each R<1 >heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as separate enantiomers of the compounds and salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain, anxiety and functional gastrointestinal disorders.
Owner:ASTRAZENECA AB

Serotonin transporter (sert) inhibitors for the treatment of depression and anxiety

The present invention relates to trans-derivatives of formulawherein R1, R2, R3, and the dotted line are as defined herein and to pharmaceutically acceptable acid addition salts thereof.The compounds of formula I are good inhibitors of the serotonin transporter (SERT inhibitors) and simultaneously, they have good activity on the NK-1 receptor (dual effect). By virtue of their efficacy as SERT inhibitors, the compounds in the present invention are particularly useful for the treatment of CNS disorders and psychotic disorders, in particular in the treatment or prevention of depressive states and / or in the treatment of anxiety.
Owner:F HOFFMANN LA ROCHE INC

Use of traditional Chinese medicine in preparing medicine for treating anxiety neurosis

The invention provides a Chinese traditional medicine combination which is applied to preparing anxiety neurosis medicines. Proved in the clinical experiments, the medicine combination has functions of supplementing qi and nourishing yin, promoting coronary arteries circulation to remove obstruction in the heart-vessels, tranquillizing and regulating main nerves through three ways of nourishing, preserving and restraining, so as to effectively relieve worrying mood of the anxiety neurosis patients and improve regulation and control ability for various functions of organism and have no obvious side effects; thus being good for clinical promotion and application.
Owner:HEBEI YILING MEDICINE INST

Substituted spirocyclic amines useful as antidiabetic compounds

Substituted spirocyclic amines of structural formula I are selective antagonists of the somatostatin sub-type receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.
Owner:MERCK SHARP & DOHME CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products